Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.52 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.52 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9085786 | 0.83 | EGLN1 (0.55) | EGLN1FTOBBOX1KDM4EALDH1A1 | |
| SCHEMBL522160 | 0.80 | EGLN1 (0.43) | EGLN1FTOBBOX1ALDH1A1LMNA | |
| SCHEMBL522448 | 0.80 | EGLN1 (0.39) | EGLN1FTOBBOX1ALDH1A1LMNA | |
| SCHEMBL27773936 | 0.79 | EGLN1 (0.59) | EGLN1FTOBBOX1KMT2A | |
| SCHEMBL521966 | 0.78 | EGLN1 (0.50) | EGLN1FTOBBOX1ALDH1A1L3MBTL1 | |
| SCHEMBL2017928 | 0.78 | EGLN1 (0.58) | EGLN1FTOBBOX1KDM4EALDH1A1 | |
| SCHEMBL28095466 | 0.77 | EGLN1 (0.58) | EGLN1FTOBBOX1KDM4EALDH1A1 | |
| SCHEMBL522787 | 0.74 | EGLN1 (0.65) | EGLN1FTOBBOX1KDM4EALDH1A1 | |
| SCHEMBL2015310 | 0.72 | EGLN1 (0.59) | EGLN1FTOBBOX1KDM4EALDH1A1 | |
| SCHEMBL5135511 | 0.72 | EGLN1 (0.55) | EGLN1FTOBBOX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357175-A1 | isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | Fibrogen, Inc. (US) | 2011-08-17 | — | — | EP | claimed |
| EP-1644336-B1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN INC (US) | 2011-01-19 | — | — | EP | claimed |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. | 2007-07-05 | — | — | US | claimed |
| US-20120029011-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2012-02-02 | — | — | US | disclosed |
| US-20110263644-A1 | Compounds and Methods for Treatment of Stroke | FIBROGEN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-8017625-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-2357175-A1 | isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | Fibrogen, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110065771-A1 | INFLAMMATORY BOWEL DISEASE THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-17 | — | — | US | disclosed |
| US-20110015223-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| EP-1644336-B1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN INC (US) | 2011-01-19 | — | — | EP | disclosed |
| US-7863292-B2 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263644-A1 | Compounds and Methods for Treatment of Stroke | PLAT, SERPINE1, PLG | EGLN1 740/4885FTO 3629/4885BBOX1 982/4885 |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885FTO 2745/4885BBOX1 160/4885 |
| US-20110015223-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | EGLN1 21/4885FTO 2512/4885BBOX1 1307/4885 |
| US-20120029011-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885FTO 2745/4885BBOX1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.